Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Gary Nachman maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and lowers the price target from $21 to $18.
Canaccord Genuity analyst Gary Nachman maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and lowers the price target from $21 to $18.